Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Violence reduction efforts should be modeled on noncontagious diseases, which have as their root cause environmental determinants, not contagious diseases.
AMA J Ethics. 2018;20(5):513-515. doi:
10.1001/journalofethics.2018.20.5.corr1-1805.
Gary Slutkin, MD, Charles Ransford, MPP, and Daria Zvetina
Violence reduction efforts should focus on interrupting transmission of violence and changing behaviors rather than mitigating environmental risk factors.
AMA J Ethics. 2018;20(5):516-519. doi:
10.1001/journalofethics.2018.20.5.corr2-1805.
Carrie A. Bohnert, MPA, Aaron W. Calhoun, MD, and Olivia F. Mittel, MD, MS
Research and training are needed so that physicians are able to identify human trafficking victims and refer them to appropriate trauma-informed treatment.
AMA J Ethics. 2017;19(1):35-42. doi:
10.1001/journalofethics.2017.19.1.ecas4-1701.